EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieMultizentrische Studie

Comparing the Cognitive Effects of Repeated Intravenous Ketamine and Electroconvulsive Therapy in Patients With Treatment-Resistant Depression

Kristina T Kumpf, Samuel T Wilkinson, Bo Hu, Ruoying Chen, Kamini Krishnan, Shinjon Chakrabarti, Taeho Greg Rhee, Tiffany Grezmak, Sanjay J Mathew, Gerard Sanacora, James W Murrough, Fernando S Goes und 3 weitere

The Journal of Clinical Psychiatry · 2025

DOI: 10.4088/jcp.25m15781 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Psychiatry, 2025. Verfasst von Kristina T Kumpf und 14 weiteren Autor:innen. Beteiligte Einrichtung: Yale School of Medicine, New Haven, Connecticut. Hauptthemen laut MEDLINE: Ketamine, Depressive Disorder, Treatment-Resistant, Electroconvulsive Therapy, Cognition. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Gefördert von: NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Electroconvulsive therapy (ECT) has potent antidepressant effects yet can lead to neurocognitive side effects. Ketamine is a rapid-acting antidepressant, which may be an alternative to ECT. Few have directly compared the cognitive effects of ECT and ketamine treatment.

Methods

We compared cognitive effects of intravenous ketamine and ECT in patients with treatment-resistant depression (TRD), collected through a multisite, randomized trial conducted between April 2017 and November 2022 (the ELEKT-D study). Participants received 6 IV ketamine treatments or 9 ECT sessions. Cognitive functioning was assessed through 4 validated cognitive tasks at pre- and posttreatment visits. The Squire Memory Complaint Questionnaire (SMCQ) and Global Self-Evaluation of Memory (GSE-My) were used to measure changes in memory functioning. Responders (those who achieved ≥50% reduction in depressive symptoms) were evaluated again at 1-, 3-, and 6-month follow-up visits.

Results

In the intent-to-treat sample (N = 365), ECT recipients performed significantly worse than ketamine recipients on all cognitive tasks at end of treatment (P < .001), with no significant differences in task performance associated with response to either treatment. Among responders, we observed no significant group differences at 1-, 3-, and 6-month follow-up. Analyses of subjective memory questionnaires were mixed. SMCQ scores improved for both groups with ketamine recipients reporting greater functional gains; ketamine-treated patients reported improvements in GSE-My scores while ECT-treated patients reported a decline in GSE-My scores. Within-group analyses in the ketamine group found improvements in executive functioning and cognitive flexibility. This survived adjustments for changes in depression, suggesting partial independence of cognitive and mood effects.

Conclusions

Patients treated with ketamine demonstrated superior cognitive functioning compared with those treated with ECT following a 3-week treatment course, with no differences between treatments observed among responders in follow-up. Findings support the short-term superiority of ketamine on cognitive functioning and the long-term cognitive safety of both treatments for TRD. Trial Registration: ClinicalTrials.gov identifier: NCT03113968.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KetamineDepressive Disorder, Treatment-ResistantElectroconvulsive TherapyCognitionHumansFemaleMaleMiddle AgedAdultAdministration, IntravenousTreatment OutcomeAged

Substanzen

Ketamine

Autor:innen und Institutionen

  • Yale School of Medicine, New Haven, Connecticut.
  • Corresponding Author: Samuel T. Wilkinson, MD, Department of Psychiatry, Yale School of Medicine, 100 York Street, New Haven, CT 06511 (Samuel.wilkinson@yale.edu).
  • Duke University, Durham, North Carolina.
  • Cleveland Clinic, Cleveland, Ohio.
  • Neuropsychology Associates of Fairfax, Fairfax, Virginia.
  • Case Western Reserve University, Cleveland, Ohio.

Förderung

  • NIA NIH HHS

Zitieren

APA

Kumpf, K. T., Wilkinson, S. T., Hu, B., Chen, R., Krishnan, K., Chakrabarti, S., Rhee, T. G., Grezmak, T., Mathew, S. J., Sanacora, G., Murrough, J. W., Goes, F. S., Collins, K. A., Barnett, B. S., & Anand, A. (2025). Comparing the Cognitive Effects of Repeated Intravenous Ketamine and Electroconvulsive Therapy in Patients With Treatment-Resistant Depression. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.25m15781

Vancouver

Kumpf KT, Wilkinson ST, Hu B, Chen R, Krishnan K, Chakrabarti S, et al. Comparing the Cognitive Effects of Repeated Intravenous Ketamine and Electroconvulsive Therapy in Patients With Treatment-Resistant Depression. The Journal of Clinical Psychiatry. 2025. doi:10.4088/jcp.25m15781

BibTeX
@article{Kumpf2025,
  author = {Kumpf, Kristina T and Wilkinson, Samuel T and Hu, Bo and Chen, Ruoying and Krishnan, Kamini and Chakrabarti, Shinjon and Rhee, Taeho Greg and Grezmak, Tiffany and Mathew, Sanjay J and Sanacora, Gerard and Murrough, James W and Goes, Fernando S and Collins, Katherine A and Barnett, Brian S and Anand, Amit},
  title = {Comparing the Cognitive Effects of Repeated Intravenous Ketamine and Electroconvulsive Therapy in Patients With Treatment-Resistant Depression},
  journal = {The Journal of Clinical Psychiatry},
  year = {2025},
  doi = {10.4088/jcp.25m15781}
}
Kostenlos starten →